Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;88(2):291-320.
doi: 10.1016/j.jaad.2021.12.065. Epub 2022 Feb 12.

Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation

Dayoung Ko  1 , Rebecca F Wang  1 , David Ozog  1 , Henry W Lim  1 , Tasneem F Mohammad  2
Affiliations
Review

Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation

Dayoung Ko et al. J Am Acad Dermatol. 2023 Feb.

Erratum in

  • Correction.
    [No authors listed] [No authors listed] J Am Acad Dermatol. 2023 Jul;89(1):195. doi: 10.1016/j.jaad.2023.04.004. Epub 2023 Apr 11. J Am Acad Dermatol. 2023. PMID: 37074242 No abstract available.

Abstract

Key challenges in the management of pigmentary disorders such as melasma and postinflammatory hyperpigmentation are their resistance to treatment, tendency to recur after treatment, and the risk of exacerbating hyperpigmentation with many treatment modalities. The second article in this 2-part continuing medical education series on pigmentary disorders focuses on the evidence behind medical and procedural treatments of dyschromias, including photoprotection, topical lightening agents, oral agents, chemical peels, and laser therapy.

Keywords: Q-switched lasers; ablative fractionated lasers; chemical peels; hydroquinone; intense pulsed light; lasers; lightening cosmeceuticals; melasma; nonablative fractionated lasers; oral lightening agents; photoprotection; picosecond lasers; pigmentary disorders; postinflammatory hyperpigmentation; sunscreen; topical lightening agents.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr. Lim is an investigator for Incyte, L’Oréal, Pfizer, and the Patient-Centered Outcomes Research Institute; has served as a consultant for Pierre Fabre, ISDIN, Ferndale Healthcare, La Roche-Posay, and Beiersdorf; and has participated as a speaker in general educational sessions for La Roche-Posay and Cantabria Labs. Dr Mohammad is an investigator for Unigen, AVITA Medical, Arcutis Biotherapeutics, Incyte, National Institute of Allergy and Infectious Diseases, and Estée Lauder. Drs Ko, Wang and Ozog have no conflicts of interest to declare.

LinkOut - more resources